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After read ing this article, the reader should be able
to:
• Understand the types of management strategies
for asthma; and
• Discuss the evidence behind current asthma
ma nagement strategies, and be confident in
making recommendations to patients andGf's.
Case study
Mr RB, a 24 -year-old non-smoker, comes into your
pharmacy and asks for a salbutamol inhaler. tie says
he normally has a prescript ion for it but he has run out
of repeats. You check his dispensing history and see
that Mr RB has consistently received one budesonide
200 mcg turbuhalar every six to eight weeks and two
salbutamol inhaters every month, over the last 18 months.
You ask him how often he requires hIS salbutamol and he
replies that he needs to use it every morning, and then
occasionally throughout the day. He says that his asthma
'has always been pretty bad' and he is 'used to putting
up with it:
Introducti on
Asthma is recognised as a National Health Pr iority Area
in Australia, and is responsible for significant morbidity
and mortality in the cummunity. International popu lation-
based studies suggest that Australia has one of the highest
prevalence rates for asthma in the world,' affecting an
estimated two million people.' Exacerbations of asthma
lead to approximately 40,000 hospitalisations and 105,000
emergency department visits annually.' Despite the existence
of national init iatives aiming to improve asthma care:·5
findings from a recent National Health Survey showed that
the management of asthma remains suboptimal.' Significant
clinical problems persist. including under-treatment with
inhaled corticosteroids (ICSI, over-reliance on reliever
medications, and poor patient self-management skills.' It
is well-recognised that the achievement and maintenance
of asthma controt reduces the risk of acute exacerbat ions
and improves prognosis. To achieve and maintain asthma
control for prolonged periods, recommendations for asthma
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management have been made in a number of interre lated
areas. The focus of this article is to review the evidence for
the strategies used to optima lly manage asthma and prevent
exacerbations,
The Austra lian Asthma Management Plan
The Australian Asthma Management Plan' was published
in 1989 by the National Asthma Council (NAC),' and was
the first of many international, consensus-based asthma
guidelines. It provides guidance and recommendations for
heaith professiona ls in the management of asthma according
to a six-stepplan. The Asthma ManagementPlan is a dynamic
document. which has been modif ied to reflect changing
evidence in best practice. Although theavailability of newer
medica tions has altered the means by which best lung
function is achieved and mainta ined, theunderlying concepts
of the plan haveremained the sarno .
There is now good evidence that particular elements of tho
Asthma Management Plan improve patient self-management
through monitoring asthma symptoms, seekingregular medical
review, and using a written Asthma Action Plan IAAP).'
Evidence-based review, based on randomised controlled trials
{RCTs!. has demonstrated the eff icacy of some aspects of the
plan but could find no evidence in favour of other aspects'
For example, there is good evidence of the effectiveness of
preventive medications, reliever medications and symptom
controllers [lonq-actinq beta-2-agonists; ILABAslJ in the
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and the avoidance of trigger factors for asthma is not strong.
Importantly, thereview found strong evidence for theprovision
of training in self-management involving sel f-monitoring of
symptoms, regular medical review and use of writtenAAPs in
adults. The As thma Management Plan rema ins the backbone
of asthma care in Australian clinical practice.
Asthma Cycle of Care
In recognition of the signif icant burden that asthma places
on the Australian cornmunitv in terms of hea lth, social,
economic and emotional costs, Australian Health Ministers
announced asthma as a National Health Priority Area in 1999.'
Subsequently, the Commonwealth Government announced
the $48.4 mill ion National GP Asthma Initiative in the 2001
Nationa l Health Budget to improve hea lth outcomesof people
with moderate-to-severe asthma." The GP Asthma lnitiative
promotes the use of the Asthma Cycle of Care (formerly the
Asthma 3+Visit Plan], which utilises a structured approach to
asthma care, as thebest practice modelof managingasthma.
recognising that effective long-term management requires
ongo ing care and regular review, The Asthma Cycle of Care
encourages partnerships in proactive asthma care between
the patient and their health professionals, and involves at
least two asthma-related consultations within 12 months for a
patient with moderate to severe asthma. The visits include an
assessment of asthma severity and level of asthma control, a
review of the patient's use of asthma medica tion anddevices,
asthma self-management education, and the development of
an AAP. Systematic review has shown that people who see
their GP regularly, receive education in self-management and
have a wrinen AAP require significantly fewer emergency
department visits, hospital admissions, days off work or
school and unscheduled doctor visits, and have significantly
reduced nocturnal asthma symptoms and significantly higher
quality of life scores.'
Ongoing patient education is a vital component of the
partnership between patients and healthcare professionals,
and can contribute to successful asthma care." However. it
has been demonstrated that the acquisition of knowledge by
patients dues not necessa rily translate into effective self -
management behaviour" It is therefore imperative that the
patient not only understands their condition, including the
purpose of medication and correct inha lation technique, but
also the importance and value of self-management of their
asthma.
Asthma Action Plans
An integral part of the Asthma Cycle of Care is the
development of a written AAP. which helps the pat ient or
carer recogniseworseningasthma. AAPs have become a core,
albeit under-utilised. component of asthma management in
Australia in accordance with best practice guidelines. The
function of a written AAPis to prov ide the patient with a set
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of rules by which to alter therapy. dependent on either peak
expiratory flow monitoring or symptom levels, The implication
is that an appropriate. early response to deterioration will
prevent dangerous exacerbations and will genera lly improve
health-related quality of life. AAPs contain the following
essential components:
i) Instructions on when and how to intensify treatment:
ii) The duration of the. treatment increase; and
iiil When to cease self-management aod seek med ical
help"
A key objective of AAP use is to help people with asthma
to mon itor themselves and their own actions, learn from
these actions to support self-care behaviours. and then
integrate these into their daily routines." Increasing patient
participation in their own care has bep.n assnciated with
significantly improved asthma symptoms and adherence
with preventive med ication, as well as significantly fewer
hospitalisations, days off school or work and reduced need
for reliever medication" It has also been found that the
possession of a written AAP reduces the risk of death from
asthma by 70%."
Ongoing patient education
is a vital component of the
partnership between patients and
healthcare professionals, and can
contribute to successful asthma
care,
Regular ICS therapy
Current Australian guidelines recommend that all patients
with persistent asthma of all levels of sev.erity use ICS as
preventive therapy" ICS are currently themost effective anti-
inflammatory medication for the management of persistent
asthma. Studies have demonstrated their efficacy in reducing
asthma symptoms." improving lung function," controlling
airway inll ammation," reducing the frequency and severity
of exacerbations," andreducing asthma mortality." However,
they do not cure asthma. and when they are discontinued.
deterioration of clinical control follows within weeks to
months in a proportion of patients." It iswell established that
in adults, persistent asthma requires long-term preventive
medication to mainta in good control." Evidence-based
guidelines over the past decade, including the NAC's six-step
Asthma Management Plan, have emphasised the importance
of the regular use of anti-inflammatorydrugs (preferably ICSj
as first-line therapy for anything more severe than occasional
mild asthma, and a shift of approach away from reliance
on relievers. There have he.en a number of studies in the
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interna tional literature indicating that a hiqh usage of reliever
medication, relative to preven ter medication, is associated
with poorer clinical ou tcomes of asthma, incloding increased
emergency department visits and hospital admissions." !
Short-acting beta-2-agonists are recommended in all stages
of asthma on an as-needed basis only. Asthma guidelines
recommend that maintenance ICSbe prescribed at thelowest
effectivedose accord ing tn the severity of the condition." It is
essential that the ICS treatment is individualised, as too high
a dose may result in adverse effects and too Iowa dose may
result in under- treatment and poorasthma control.
A systematic review of ACTs demonstrated that the addition
of a lA BA to ICS therapy improves asthma symptoms. The
addition of l ABA has an ICS-sparing effect, which permits
a reduct ion in ICS maintenance dose." Specifically, studies
that compared reduced dose ICS/LABA combination to
a fixed moderate-to-high dose ICS reported significant
improvements in lung function and percent rescue free days
with the ICS/ l /\B/\ combination therapy." However, the
review also found no significant difference in the number
of severe exacerbations requiring oral corticosteroids when
comparing the combination to ICS alone. Greenstone, et a',
reported similar findings, concluding that there is noapparent
superiority of adding LABA to ICS in terms of exacerbations,
bot improved symptoms and long function tests favours
additional LABA therapy" The NAC recommends a LABA
should be the first choice for add-on therapy in patients for
whom adequate asthma control is not achieved despite low
dose ICS treatment. otter roling oot pooradherence and poor
inhalation technique as causes." In an attempt to improve
adherence, devices are ava ilable combining ICS and l ABA
therapy in a single inhaler.
Ma intenance and reliever therapy
In light of the growing evidence that many patients neglect
their preventer medication and over-rely on reliever
medication, a new asthma manauement strategy has recen tly
been evalua ted in a series of clinical trials."' " The strategy
util ises a single inhaler containing an ICS (budeson ide) and
a lABA leformoteroll for both maintenance therapy and
symptomrelief. For patients with persistent asthma symptoms
despite the regular use of ICS, studies have found that
fewer severe exacerbations occurred with the maintenance
and reliever regimen when compared to the conventional
combination regimen of regular ICS plus a short-acting beta-
2-agonist when required. Table 1 summarises the results of
COMPASS, the only published double-blind trial where the
maintenance and reliever reg imenwas compared toa higher-
dose convent ional reg imen.28
InAugust 2007, thePharmaceutical Benefits Scheme hstmq of
budesonide with eformotero I 100/6~g and 200/6~g ISymbicortj
was extended to allow Australianswho experience frequent
asthma symptoms while receiving combinat ion ICS/LABA
therapy or ICS alone to use the aiternative budesonide with
efarmoterol maintenance and reliever regimen." The NAC
has endorsed this new regimen (commonly ca lled Symbicort
Tab le 1. Rates of severe exacerbations in the COMPASS triaF6
Treatment group Severe exacerbat ions per 100 Average daily les dose
patients per six months (budesonide equivalentl
Budesanidewith eformaterol 12" 604~g
Imaintenance and reliever regimen)
n = 1107
Budesonide with eformoterol plus terbutaline 16 800~g
asneeded (conventional regimen!
n = 11 05
Fluticasanewith salmeterol plus terbutaline 19 800 ~g
as needed (conventional regimen)
n =1123
"Thenumberof severe exacerbationswas significantly less thanwith lhe budesonide with eformoterol conventional reg imen
IP= 0.00481and also significantly less than with the Iluticasone with salmeterol conventional regimen (P< 0.001!.
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Maintenance And Reliever Therapy: SMART). with a SMART-
specific written AAP nowavailable."
Whilethe drug treatments used in the management of asthma
have proven efficacy, effective management strategies and
adherence with therapy are imperative to reduce the morbidity
andmortality associa tedwith the condition. Even in patients
with uncontrolled asthma. guideline-defined control can be
ach ieved and maintained with appropriate treatment." The
aforementioned strategies are useful and provenapproaches
to aid in the ach ievement of treatment goals in asthma, and
should be promoted bypharmacists.
Case study
You advise M, RB that he shouldn't have to put up with
his asthma symptoms as evidence has demonstrated that
even patients with severe asthma can gain control of their
symptoms with appropriate therapy. You indicate to M,
RB that you are concerned that his asthma could be better
cunuotled, and recommend that he see his GP as soon as
possible for a review of his asthma therapy, and for the
development of an lndividualised Asthma Action Plan. You
provide Mr RB with a salbutamol inhale' to use in the interim
and check his inhale' technique. You also provide him with
some educational materials fromthe Asthma Foundation and
the Pharmacy Self Care Fact Cards on Asthma and Asthma
Medicines.
Bonnie Bereznicki. Or Iekn Rp.[p. lnicki and Professor Gregurv Peterson are
from the Unit tor MedicationOutcomes Research andEducation. School of
Pharmacy, University of Tasmania.
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